BamSEC and AlphaSense Join Forces
Learn More

Heron Therapeutics Inc. – Material Contracts

NASDAQ: HRTX    
Share price (5/22/26): $0.86    
Market cap (5/22/26): $163 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 8-K 16 pages Heron Therapeutics, Inc. Amended and Restated Management Retention Agreement
12/34/56
EX-10.3
from 8-K 15 pages Heron Therapeutics, Inc. Amended and Restated Management Retention Agreement
12/34/56
EX-10.2
from 8-K 16 pages Heron Therapeutics, Inc. Amended and Restated Management Retention Agreement
12/34/56
EX-10.1
from 8-K 19 pages Amended and Restated Executive Employment Agreement
12/34/56
EX-10.26
from 10-K 4 pages Amendment No. 7 to Co-Promotion Agreement
12/34/56
EX-10.18
from 10-K 73 pages Certain Information Has Been Omitted in Accordance With 601(b)(10) of Regulation S-K Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential Omissions Are Marked [***]
12/34/56
EX-10.6
from 10-K 43 pages Agreement of Sublease
12/34/56
EX-10.5
from 10-K 12 pages Indemnification Agreement
12/34/56
EX-10.4
from 10-K 10 pages Heron Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan Notice of Restricted Stock Unit Grant
12/34/56
EX-10.3
from 10-K 12 pages Heron Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan Notice of Stock Option Grant
12/34/56
EX-10.8
from 10-Q 3 pages Certain Information in This Exhibit Has Been Excluded in Accordance With Item 601(b)(10) of Regulation S-K Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Redactions Are Marked [***]. Amendment No. 6 to Co-Promotion Agreement
12/34/56
EX-10.7
from 10-Q 91 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Office Lease Agreement Between Usef Hcg Fenton LLC (As Landlord) and Heron Therapeutics, Inc. (As Tenant) Dated August 22, 2025
12/34/56
EX-10.1
from 10-Q 25 pages Certain Identified Information Has Been Excluded From This Exhibit Because It Is Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. [***] Indicates That Information Has Been Redacted. Framework Agreement
12/34/56
EX-10.1
from S-3 79 pages Note Purchase Agreement
12/34/56
EX-10.5
from 8-K 79 pages Securities Purchase Agreement
12/34/56
EX-10.4
from 8-K 79 pages Note Purchase Agreement
12/34/56
EX-10.3
from 8-K 28 pages Heron Therapeutics, Inc. Exchange Agreement August 8, 2025
12/34/56
EX-10.2
from 8-K 73 pages Certain Information Has Been Omitted in Accordance With Item 601(b)(10) of Regulation S-K Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. Omissions Are Marked [***]
12/34/56
EX-10.1
from 8-K 16 pages Cooperation Agreement
12/34/56
EX-10.4
from 10-Q 3 pages Amendment No. 5 to Co-Promotion Agreement
12/34/56